Nova Patents
AT466084T

Hla-a24-restricted cancer antigen peptide

Abstract

Providing a derived from WT1, wherein the inner to induce the active CTLs HLA-A24 restrictive peptide and a to the peptide the polynucleotide and uses the peptide or polynucleotide cancer vaccine is in - vivo variant, wherein waits. Use of the invention claims a vaccine to be more of patients.

Term

No projected expiry on record.

  1. Priority
  2. Filed
  3. Granted
  4. Today

24 members in 11 offices

This recordMember, by publication datePriority claim1 more office is in the list below

Priority claims3

Priority claims
DocumentOfficeKindDate
2002171518JapanA
2002275572JapanA
0307463JapanW

Members24

Family members, oldest first
DocumentOfficeKind
CA2489227A1CanadaA1
WO03106682A1World Intellectual Property Organization (WIPO)A1
AU2003242305A1AustraliaA1
AU2003242305A8AustraliaA8
KR20050010913ARepublic of KoreaA
EP1536009A1European Patent Office (EPO)A1
CN1675362AChinaA
JPWO2003106682A1JapanA1
EP1536009A4European Patent Office (EPO)A4
HK1083866AHong Kong, ChinaA
US2007082860A1United States of AmericaA1
CN101113163AChinaA
CN100408683CChinaC
US7420034B2United States of AmericaB2
US2009099090A1United States of AmericaA1
JP4365784B2JapanB2
US7666985B2United States of AmericaB2
EP1536009B1European Patent Office (EPO)B1
AT466084TThis recordAustriaT
ATE466084T1AustriaT1
DE60332355D1GermanyD1
CN101113163BChinaB
KR101050703B1Republic of KoreaB1
CA2489227CCanadaC